The Food and Drug Administration reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.
The agency told Moderna earlier this month that it would not review the submission because of a dispute over the design of a clinical trial. The decision was made by top FDA official Vinay Prasad, who STAT previously reported had overruled career scientists in the vaccine center.